Antipsychotic Use and the risk of rhabdomyolysis

Kathleen Packard, Paul Price, Ashley Hanson

Research output: Contribution to journalArticlepeer-review

29 Scopus citations


Rhabdomyolysis is not a well-understood adverse effect of antipsychotic use. Proposed mechanisms suggest involvement of serotoninergic and/or dopaminergic blockade. The purpose of this study was to describe the relationship between antipsychotic use and rhabdomyolysis. Patients admitted with rhabdomyolysis and taking an antipsychotic from January 2009 to October 2011 were included. Background demographics, laboratory data, medical and physical history, concomitant medications, and hospital course data were collected. Of the 673 cases admitted with rhabdomyolysis, 71 (10.5%) were on an antipsychotic. This is significantly greater when compared to the general US population, where only 1.3% of individuals take an antipsychotic drug (P

Original languageEnglish (US)
Pages (from-to)501-512
Number of pages12
JournalJournal of Pharmacy Practice
Issue number5
StatePublished - Oct 12 2014

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)


Dive into the research topics of 'Antipsychotic Use and the risk of rhabdomyolysis'. Together they form a unique fingerprint.

Cite this